Phaseline

Companies › VectivBio

VectivBio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apraglutide
GLP-2 receptor agonist
GLP2RPhase 3Short Bowel Syndrome; Short Bowel Syndrome (SBS)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05018286ApraglutidePhase 3Short Bowel SyndromeGastroenterologyOct 2027
NCT07742735ApraglutidePhase 3Short Bowel Syndrome (SBS)GastroenterologyOct 2028

Targets

GLP2R (1)

Companies with the same targets

Chongqing Peg-Bio Biopharm Takeda

Companies built like this

Camurus Altimmune Pharmicell Akero Therapeutics LyGenesis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.